Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00420355 · ClinicalTrials.gov registry record · Phase 4

Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients

A Phase 4 study, sponsored by University of Oklahoma.

Terminated
Registry status
Phase 4
Development phase
19
Enrollment target

NCT00420355 is a Phase 4 study that was terminated before completion, run by University of Oklahoma. The registered enrollment target is 19 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00420355, a Phase 4 study, was terminated before completion, sponsored by University of Oklahoma.

TERMINATED
Registry status
Phase 4
Development phase
19 participants
Enrollment target

Study Summary

The objective of this study is to determine the pharmacokinetics of lopinavir, ritonavir, and atazanavir when lopinavir/ritonavir and atazanavir are used in combination.

Interventions

  • DRUG atazanavir
  • DRUG lopinavir/ritonavir

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2007-04
Est. Completion 2008-09
Phase Phase 4

Sponsor

University of Oklahoma

358 total trials

What the Registry Record Tells You About NCT00420355

The ClinicalTrials.gov registry entry for NCT00420355 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which atazanavir is the first listed.

NCT00420355 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00420355 about?

NCT00420355 is a clinical study titled "Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients". The objective of this study is to determine the pharmacokinetics of lopinavir, ritonavir, and atazanavir when lopinavir/ritonavir and atazanavir are used in combination.

What is the current status of trial NCT00420355?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2007-04. Estimated completion is 2008-09.

What interventions are being tested in trial NCT00420355?

The interventions under investigation include: atazanavir (DRUG), lopinavir/ritonavir (DRUG).

Who is sponsoring clinical trial NCT00420355?

This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.